PsychopharmacologyApril 8, 2025Megan L Bertholomey, Camryn Forbes, Bryan D McElroy et al.3 citations
Alcohol use and major depressive disorder are frequently comorbid, with individuals diagnosed with a substance use disorder being nearly three times as likely to have major depression. Poor treatment responses are found for both disorders and are further complicated when they co-occur, underscoring the need for better therapies. One potential candidate is ketamine, which has been shown to have...
Mindfulness improves mental health and clinical conditions including psychosis and modulates attentional processes including salience-the automatic direction of attention to prominent elements. Aberrant salience-the exaggerated significance attribution to perceived elements-is associated with psychotic experiences, but its interactions with mindfulness remain unexplored. This...
Obesity is a multifactorial disorder involving a behavioural aetiology in subsets of patients that traditional therapeutic approaches have failed to address. Drawing parallels with addiction, the rewarding aspects of a chronic energy-dense diet can compromise dopaminergic reward circuits, eventually causing individuals to become habitually responsive to food-related stimuli despite adverse...
Introduction: Depression, affecting 350 million people globally, is a leading cause of disability. Common symptoms include low mood, sadness, guilt, anxiety, and suicidalthoughts. Current treatments, mostly monoamine-based antidepressants, have limitations such as delayed effects and low efficacy, with over 60% of patients not achieving lasting remission. Ketamine, an NMDA antagonist, has shown...
Case Report Esketamine in Geriatric Depression and Pseudodementia: A Case Study Filippo Mazzoni 1,2, Giovanni Carnevale Miacca 1,2, Alessandro Guffanti 1,2, Vassilis Martiadis 3, Benardo Maria Dell’Osso 4,5,6,7, Natascia Brondino 1,2 and Miriam Olivola 1,4 1 Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy 2 Department of Mental Health and Addiction, ASST...
Ketamine is an NMDA receptor antagonist, long used for its anesthetic and pain reducing properties, but has more recently demonstrated efficacy for treating depression. Evidence is also emerging for other psychiatric indications including posttraumatic stress disorder, anxiety disorders, obsessive compulsive disorder, and to support psychotherapy. In this context, there is greater demand for...
Psilocybin, a classic psychedelic, has therapeutic potential for psychiatric disorders. A specific brain circuit and receptor have now been found to be required for psilocybin’s long-term effects on neural plasticity and depression-related behaviour. The psychedelic psilocybin’s beneficial behavioural action depends on the activation of pyramidal-tract neurons in the frontal cortex.
This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery from moral injury. Moral injury (MI), characterized by profound psychological distress arising from morally challenging experiences, has garnered increased attention as a complex mental health concern with significant functional sequelae, especially...
Psilocybin has various therapeutic effects in mental and psychological disorders, including depression and mood disorders, obsessive-compulsive disorders, substance addiction and anxiety. Pharmacodynamic properties of psilocybin depend on doses used and time after administration. The psilocybin dose range varies depending on whether it is used therapeutically or for recreational purposes in...
Psilocybin, a naturally occurring psychedelic compound in magic mushrooms, shows promise as a novel intervention with a single administration inducing rapid and long-lasting antidepressant effects. However, there are limited studies on the optimal dosing required for the beneficial effects of psilocybin given its side effects. To address this gap, we investigated in Wistar rats whether a single...